Bank of America initiated coverage on shares of Pfizer (NYSE:PFE) in a research note issued to investors on Wednesday, The Fly reports. The brokerage issued a neutral rating and a $37.00 price target on the biopharmaceutical company’s stock.
Other research analysts have also issued research reports about the stock. UBS Group restated a neutral rating and set a $43.00 price target on shares of Pfizer in a research note on Monday, August 5th. Morgan Stanley cut their price target on shares of Pfizer from $40.00 to $38.00 and set an equal weight rating on the stock in a research note on Tuesday, August 27th. Zacks Investment Research upgraded shares of Pfizer from a sell rating to a strong-buy rating and set a $38.00 price target on the stock in a research note on Tuesday, October 1st. Credit Suisse Group restated a neutral rating on shares of Pfizer in a research note on Monday, August 12th. Finally, ValuEngine upgraded shares of Pfizer from a sell rating to a hold rating in a research note on Wednesday, October 2nd. Twelve investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Pfizer has an average rating of Hold and an average price target of $44.47.
NYSE:PFE traded up $0.22 during midday trading on Wednesday, reaching $36.56. 677,026 shares of the stock traded hands, compared to its average volume of 18,255,412. Pfizer has a 12-month low of $33.97 and a 12-month high of $46.47. The business has a 50-day moving average of $36.13 and a two-hundred day moving average of $39.79. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.21 and a current ratio of 1.47. The stock has a market capitalization of $200.78 billion, a PE ratio of 12.17, a price-to-earnings-growth ratio of 2.89 and a beta of 0.66.
Pfizer (NYSE:PFE) last posted its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The company had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. During the same quarter in the prior year, the company posted $0.77 earnings per share. Pfizer’s revenue for the quarter was down 1.5% compared to the same quarter last year. Research analysts anticipate that Pfizer will post 2.81 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.94%. Pfizer’s payout ratio is currently 48.00%.
In other Pfizer news, Director Scott Gottlieb acquired 3,000 shares of the business’s stock in a transaction dated Friday, August 23rd. The shares were purchased at an average price of $34.72 per share, for a total transaction of $104,160.00. Following the completion of the purchase, the director now directly owns 3,000 shares of the company’s stock, valued at $104,160. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Pfizer Inc acquired 50,000 shares of the business’s stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $900,000.00. The disclosure for this purchase can be found here. 0.09% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. Weybosset Research & Management LLC grew its position in Pfizer by 2.0% during the second quarter. Weybosset Research & Management LLC now owns 12,847 shares of the biopharmaceutical company’s stock valued at $557,000 after buying an additional 250 shares during the period. Financial Gravity Wealth Inc. lifted its holdings in Pfizer by 33.2% during the second quarter. Financial Gravity Wealth Inc. now owns 1,031 shares of the biopharmaceutical company’s stock valued at $45,000 after purchasing an additional 257 shares in the last quarter. Intl Fcstone Inc. lifted its holdings in Pfizer by 2.4% during the second quarter. Intl Fcstone Inc. now owns 11,140 shares of the biopharmaceutical company’s stock valued at $483,000 after purchasing an additional 261 shares in the last quarter. Lee Financial Co lifted its holdings in Pfizer by 6.2% during the second quarter. Lee Financial Co now owns 4,569 shares of the biopharmaceutical company’s stock valued at $198,000 after purchasing an additional 265 shares in the last quarter. Finally, Keystone Financial Group lifted its holdings in Pfizer by 1.8% during the second quarter. Keystone Financial Group now owns 15,532 shares of the biopharmaceutical company’s stock valued at $673,000 after purchasing an additional 278 shares in the last quarter. Hedge funds and other institutional investors own 71.70% of the company’s stock.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: Insider Trading
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.